The antibody-drug conjugate has a structural feature that makes it uniquely problematic from an intellectual property standpoint: it is, by design, a composite of three distinct technologies developed by three communities of scientists who largely did not know each other. The antibody came from one tradition, the cytotoxic payload

The second week of March 2026 represented a defining period for the global life sciences sector, as the industry transitioned from the volatility of previous fiscal cycles into a phase of disciplined but aggressive capital deployment. Between March 9 and March 13, 2026, the deal landscape was characterized by a

A new paper published in Gene Therapy this week proposes securitizing 30-year performance-based annuities to solve the upfront payment problem for cell and gene therapies. The mechanics are elegant, the Monte Carlo results are encouraging, and the analogy to mortgage-backed securities is deliberately chosen. But read from

Company Overview and Technology Slate Medicines, Inc. is a privately-held, clinical-stage biotech company headquartered in Raleigh, North Carolina, focused on advancing next-generation therapeutics for migraine and other headache disorders. The company launched publicly in February 2026 alongside the close of a $130 million Series A financing, co-

Overview and Investment Focus The Dementia Discovery Fund (DDF), managed by SV Health Investors, is a transatlantic venture capital fund investing exclusively in companies developing or enabling novel therapeutics for dementia. Founded in 2015 and operating from London and Boston, DDF describes itself as the world's largest family

The Reverse Morris Trust has become Big Pharma's favourite instrument for shedding non-core assets without triggering billions in corporate tax. But for royalty investors, royalty holders, and licensors who have carefully structured their claims against a specific counterparty, an RMT is not just a tax-efficient divestiture

In December 2025, Royalty Pharma agreed to pay $275 million for a 9.25% synthetic royalty on Denali Therapeutics' tividenofusp alfa—a treatment for Hunter syndrome, a lysosomal storage disorder affecting roughly 2,000 patients in the United States. The deal carried a 3.0× cap multiple, with an

The conversation about Asia-Pacific pharmaceutical royalties tends to start and end with China. The out-licensing volume data from 2025 makes that reflex understandable, and Royalty Pharma's appointment of Kenneth Sun as Head of Asia is the clearest institutional signal yet that Western royalty capital is moving

Visual Summary Week in Numbers: $16.6B total disclosed value, $9.3B M&A, $295M+ royalty and non-dilutive capital, $838M equity financings, $8.2B debt issuances Royalty League Table: Seven royalty and non-dilutive financing transactions: Teva/Blackstone ($400M), Royalty Pharma/Zymeworks ($250M), Heidelberg/HCRx+Soleus ($45M), and

On March 2, 2026, Royalty Pharma announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Sun, formerly Head of Asia Pacific Healthcare Investment Banking at Morgan Stanley, will be based in Hong Kong and lead the company's royalty business across